{"preliminary_commentary":{"by_channel":{"x_thread":15,"youtube":9,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05020236\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"MAGNETISMM-5","nct_id":"NCT05020236","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=magnetismm-5-nct05020236. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MAGNETISMM-5","arms":[{"description":null,"label":"Part 1 Safety Lead-In Dose Escalation: Elranatamab + Daratumumab","type":"EXPERIMENTAL"},{"description":null,"label":"Part 2 Randomized Arm A: Elranatamab","type":"EXPERIMENTAL"},{"description":null,"label":"Part 2 Randomized Arm B: Elranatamab + Daratumumab","type":"EXPERIMENTAL"},{"description":null,"label":"Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"Part 3 Arm D: Elranatamab","type":"EXPERIMENTAL"},{"description":null,"label":"Part 3 Arm E: Elranatamab + Daratumumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-05-31","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":893,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Elranatamab","otherNames":["PF-06863135"],"type":"DRUG"},{"name":"Daratumumab","otherNames":["Darzalex Faspro; Darzalex solution for injection"],"type":"DRUG"},{"name":"Pomalidomide","otherNames":["Pomalyst, Imnovid"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-24","lead_sponsor":"Pfizer","official_title":"AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-02-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part 1 Safety Lead-In: Incidence of dose limiting toxicities","timeFrame":"First 42 days after first elranatamab dose"},{"measure":"Part 2 Randomized: Progression free survival per International Myeloma Working Group criteria","timeFrame":"From date of randomization to date of progressive disease, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 51 months"},{"measure":"Part 3: Frequency of treatment-emergent adverse events","timeFrame":"First 84 days after first elranatamab dose"}],"references":[],"start_date":{"date":"2021-10-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","url":"https://clinicaltrials.gov/study/NCT05020236"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/magnetismm-5-nct05020236"}